John Anderson, MD

Effect of Hypercortisolism on Cardiovascular and Diabetes Care

Video content above is prompted by the following:

How does hypercortisolism contribute to treatment-resistant hypertension and other cardiovascular diseases?

We have mentioned that there are cardiovascular risks associated with hypercortisolism. How does treatment of hypercortisolism impact these risks?

Looking specifically from a cardiology perspective, when should a cardiologist suspect hypercortisolism as a contributing factor to cardiovascular disease?

What is the role of hypercortisolism in type 2 diabetes?

How does hypercortisolism complicate the management of type 2 diabetes, and how does it impact long-term glucose control?

Now, let us shift to the endocrinology perspective. When should an endocrinologist suspect hypercortisolism in their patients with type 2 diabetes?

Videos

Experts discuss how hypercortisolism contributes to treatment-resistant hypertension and other cardiovascular diseases, the impact of treating hypercortisolism on cardiovascular risks, when cardiologists should suspect hypercortisolism as a contributing factor to cardiovascular disease, the role of hypercortisolism in type 2 diabetes, how it complicates the management of type 2 diabetes and impacts long-term glucose control, and when endocrinologists should suspect hypercortisolism in their patients with type 2 diabetes.

Dexamethasone Suppression to Identify Hypercortisolism

What risk factors and laboratory abnormalities might raise clinical suspicion for hypercortisolism?

Who should be screened for hypercortisolism?

Experts discuss risk factors and laboratory abnormalities that might raise clinical suspicion for hypercortisolism and who should be screened for hypercortisolism.

Who to Screen for Hypercortisolism

Experts discuss risk factors and laboratory abnormalities that might raise clinical suspicion for hypercortisolism and who should be screened for hypercortisolism

Importance of Primary Care in Identification and Screening for Hypercortisolism

How would the clinical presentation of hypercortisolism differ in the primary care vs specialist setting?

The prevalence of hypercortisolism in certain at-risk patients is higher than previously thought. Can you discuss some of the recent data on hypercortisolism prevalence?

Prevalence of hypercortisolism in patients with difficult-to-control diabetes was 24%.

Prevalence of hypercortisolism in patients with difficult-to-control diabetes and difficult-to-control hypertension was 40%.

Patients with cardiovascular disease had a higher prevalence of hypercortisolism than those without (33.3% vs 20.9%).

Experts discuss how the clinical presentation of hypercortisolism differs in the primary care vs specialist setting, highlighting earlier signs/symptoms vs overt disease, and review recent data on the prevalence of hypercortisolism, including its higher occurrence in patients with difficult-to-control diabetes, difficult-to-control hypertension, and cardiovascular disease.

John Anderson, MD

Articles